Please read the DISCLAIMER at the bottom of the blog.

Rakesh Jhunjhunwala is considered to be the greatest investor in Indian Market. He is supposed to have made Rs 5000 crores by just investing Rs 5000 in Indian Stock Market. Rakesh Jhunjhunwala guru mantra to be successful in stock market is as enumerated below:

(a) He advises people to become interested in a stock when none is interested in the same stock. As per him BUY RIGHT & HOLD TIGHT for years to come. He has been holding few stocks for last 10 years and he is still minting money from those stocks.

(b) He further advises that one should not follow big investors blindly as their risk profile and long term goals with time frame may be difficult to be followed by retail investor.

(c) Market is supreme and every thing is reflected in the price and thus their is no point in fighting the trend as market is always right.

(d) One should be able to create a balance between the fear and greed.

(e) As per his words one has to learn the stock market trading as none can teach the market as stock market experience is the best teacher.

Thus follow Rakesh Jhunjhunwala advice in stock market, BE PATIENT and grow big like Warren Buffet or this iconic man from Dalaal Street.

If you subscribe to this blog with your email, you will get the post right in your INBOX moment it is posted on this blog. Do remember to activate the subscription in your email. GOOD LUCK.

BSE Sensex Stock Ticker

Thursday, October 8, 2009

Lupin signs deal with Nasdaq-listed Salix Pharmaceuticals for Rifaximin (Part of Rakesh Jhunjhunwala Portfolio)

Lupin has granted Nasdaq-listed Salix Pharmaceuticals, the exclusive rights in the United States to its bioadhesive drug delivery technology for use with Rifaximin.

Lupin and Salix have entered into a deal under which both partners will collaborate in the development and commercialization of an extended release product incorporating Rifaximin and utilizing Lupin’s proprietary bioadhesive technology.

Beside this, Lupin and Salix have also entered into an exclusive agreement in the United States for supply of Rifaximin active pharmaceutical ingredient (API).

Under the arrangement, Salix has made a $5 million up-front payment and will make additional regulatory milestone payments to Lupin. In addition, Salix will pay royalties on net sales of the bioadhesive Rifaximin product to Lupin.

Rifaximin is a gut-selective antibiotic with negligible systemic absorption (<0.4%)>
Posted by sonika at 12:12 PM
Labels: , , , , , ,

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

DISCLAIMER

DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.

Website hit counters

search engine submission